364080-73-9

Upstream product

• 364080-72-8 (R)-Toluene-4-sulfonic acid 2-(6-chloro-pyridin-3-yl)-2-hydroxy-ethyl ester 
• 18162-48-6 tert-butyldimethylsilyl chloride 
• 288-32-4 1H-imidazole 

Downstream Products

• 1251957-87-5 2-[4-(2-{[(2R)-2-hydroxy-2-(pyridin-3-yl)ethyl]amino}-2-methylpropyl)phenyl]-N-(5-methylisoxazol-3-yl)acetamide 
• 1251957-77-3 2-[4-(2-{[(2R)-2-{[tert-butyl(dimethyl)silyl]oxy}-2-(pyridin-3-yl)ethyl]amino}-2-methylpropyl)phenyl]-N-(5-methylisoxazol-3-yl)acetamide 
• 1251957-76-2 lithium [4-(2-{[(2R)-2-{[tert-butyl(dimethyl)silyl]oxy}-2-(pyridin-3-yl)ethyl]amino}-2-methylpropyl)phenyl]acetate 
• 1251957-75-1 ethyl [4-(2-{[(2R)-2-{[tert-butyl(dimethyl)silyl]oxy}-2-(pyridin-3-yl)ethyl]amino}-2-methylpropyl)phenyl]acetate 
• 1251957-74-0 ethyl [4-(2-{[(2R)-2-{[tert-butyl(dimethyl)silyl]oxy}-2-(6-chloropyridin-3-yl)ethyl]amino}-2-methylpropyl)phenyl]acetate 

Relevant academic research and scientific papers

Sulfamide derivatives useful as beta3 agonists and pharmaceutical uses thereof

Sulfamide compounds having formula (I) are described as well as their use in the treatment of diseases dependent on the signaling pathways associated with β-adrenergic receptors, such as obesity, diabetes, hypertension, gastrointestinal hypo- or hyper-motility and cardiovascular diseases.

Beta3 agonists and uses thereof

Sulfamide compounds having formula (I) are described as well as their use in the treatment of diseases dependent on the signaling pathways associated with β-adrenergic receptors, such as obesity, diabetes, hypertension, gastrointestinal hypo- or hyper-mot